Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. is demonstrating a promising pipeline aimed at addressing significant unmet medical needs in retinal diseases through its Modifier Gene Therapy Platform, with the potential for substantial advancements in patient health outcomes. Recent clinical trial results indicate that the company’s OCU410 therapy has shown significant efficacy, including robust reductions in geographic atrophy lesion growth and meaningful improvements in visual function metrics compared to untreated controls. Additionally, the encouraging performance of OCU400, notably the statistically significant gains in visual acuity and stabilization effects in particular patient subgroups, bolsters confidence in the company's ability to advance towards pivotal trials, positioning it favorably within the biotechnology sector.

Bears say

Ocugen Inc's financial outlook appears negative due to challenges in securing sufficient capital for ongoing program development, potentially hindering the advancement of its therapeutic pipeline. Additionally, the data from the recent trial update suggested a diminishment in efficacy across a small control group, raising concerns about the robustness of the results and the competitive position of their therapies. The inherent risk tied to the uncertain outcomes of upcoming phase I/II/III studies further contributes to the company’s precarious financial status, where negative results could significantly depress share value.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.